Permira aims to raise $4 billion by selling contract drug manufacturer Cambrex, according to FT.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 06 2025
0mins
Should l Buy ?
Source: Reuters
Sale of Cambrex: British private equity firm Permira is selling its contract drugmaker Cambrex, aiming for a valuation of up to $4 billion, as reported by the Financial Times.
Impact of U.S. Manufacturing Push: Cambrex has benefited from a trend among global drugmakers to increase U.S. manufacturing capacity in response to proposed drug import duties by President Trump, which could lead to tariffs as high as 250%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
